Lake Street Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Lake Street analyst Thomas Flaten initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $9.
Lake Street analyst Thomas Flaten initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $9.